{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019727","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.509694+00:00","generated_at":"2026-06-15T09:07:56.210670+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials","bullets":["Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.","R&D expenses $39.5M, up $20.2M YoY driven by XEN1101 Phase 3 studies and X-NOVA MDD trial.","Cash $687.3M as of March 31, 2023; expects to fund operations into 2026.","XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) recruiting; pediatric expansion to include children ≥12.","Phase 2 X-NOVA MDD study last patient screening expected June 2023; topline data Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019727","json":"https://secwatch.observer/filing/0000950170-23-019727.json","markdown":"https://secwatch.observer/filing/0000950170-23-019727.md","text":"https://secwatch.observer/filing/0000950170-23-019727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/0000950170-23-019727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/xene-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:07:56.210670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0de7bbbf92c6d0ce6f5378eaf77a7a52221e391e","claim":"Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"the Company’s financial results for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/0000950170-23-019727-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}